The Ministry of Health announced an important measure for the treatment of HIV in the Unified Health System (SUS). From now on, the drug Dovato will be available for seropositive patients, representing a significant advance in the fight against the disease.
see more
Gene therapy eye drops bring hope to millions of people…
Better Health in Two Days: The Surprising Effectiveness of End Workouts…
Dovato, a combination of the antiretrovirals dolutegravir and lamivudine, was approved by Anvisa in 2021 and has been praised for its effectiveness and practicality. Your presentation in a single pill simplifies the treatment, making it easier and more practical for patients, who previously had to take two different pills.
The acquisition of the drug is in the final bidding phase, which will allow distribution in all states of the country by the end of 2023. This measure has the potential to benefit a significant number of patients who depend on the SUS for the treatment of HIV.
Dovato is indicated for adult patients and adolescents over 12 years old, as long as they weigh more than 40 kg and do not show known or suspected resistance to its components.
In addition to reducing the body's viral load, the medicine it also contributes to the increase of CD4 cells, essential for the patient's immune defense.
With this inclusion, SUS will now offer 29 drug options to combat HIV, reinforcing the commitment government to expand access and improve the quality of care offered to HIV-positive patients across the country.
The availability of Dovato is seen as a significant advance, not only for its proven effectiveness, but also for facilitating patient adherence to treatment. This provides a better quality of life and well-being for HIV carriers.
With this new measure, Brazil takes another step towards the eradication of the disease and the strengthening of health policies aimed at the treatment and prevention of HIV.
